Author: digi

Differences in Protocol Design for Small Molecule vs. Biologic Drugs

Stability protocols for pharmaceutical products are not one-size-fits-all. Regulatory expectations, degradation pathways, storage requirements, and testing methods vary significantly between small molecule drugs and biologics. Designing a protocol that accounts for these nuances is essential to ensure product integrity, patient safety, and regulatory compliance. In this tutorial, we compare and contrast protocol design strategies for…

Protocols and Reports, Stability Study Protocols for Different Drug Types

SOP for Conducting Stability Testing for Gene Therapy Products as per FDA Guidelines

SOP for Conducting Stability Testing for Gene Therapy Products as per FDA Guidelines Guidelines for Stability Testing of Gene Therapy Products as per FDA Guidelines 1) Purpose The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for conducting stability testing for gene therapy products in accordance with US FDA requirements. This SOP…

Stability Studies SOP

ICH Q8 Guidelines for QbD-Based Stability Design

The ICH Q8 (R2) guideline is a cornerstone document in pharmaceutical development, laying the foundation for Quality by Design (QbD) approaches. Stability studies, when aligned with QbD and ICH Q8, can move from routine testing to strategic quality tools. This tutorial breaks down how to use ICH Q8 principles to design scientifically sound, risk-based, and…

Pharmaceutical Quality and Practices, Quality by Design (QbD) in Stability Testing

How to Handle Market Complaints Related to Expiry or Shelf Life

When pharmaceutical products reach the market, real-world factors such as storage conditions, distribution timelines, and label readability can cause shelf life and expiry-related complaints. Properly handling these complaints is crucial to ensure patient safety, meet regulatory expectations, and maintain product integrity. This how-to guide walks pharma professionals through the correct procedure to manage complaints related…

Shelf Life and Expiry, Shelf Life vs. Expiration Date: Key Differences

Building an Audit-Ready Dossier Under ICH Q1A Guidelines

Creating an audit-ready dossier is essential when submitting pharmaceutical stability data to global regulatory agencies. Under the ICH Q1A(R2) guideline, all stability documentation must demonstrate consistency, traceability, and alignment with the product’s quality profile. This article outlines how pharma professionals can build a compliant, inspection-ready dossier for ICH stability studies using best practices, templates, and…

ICH Stability Guidelines (Q1A–Q1E, Q8, Q9, etc.), Regulatory Guidelines

ICH Q1A Expectations for Protocol Content and Format

Stability protocols form the backbone of pharmaceutical product shelf-life justification. Regulatory agencies such as the USFDA and ICH place significant emphasis on the protocol’s scientific soundness and compliance with established guidelines—particularly ICH Q1A(R2). This article breaks down the structure and content expectations for stability protocols under ICH Q1A(R2), with an emphasis on regulatory audit readiness…

Protocols and Reports, Stability Study Protocols for Different Drug Types

Design Risk-Based Stability Protocols Across Lifecycle and Formulations

Understanding the Tip: What is a risk-based approach to stability testing: Stability protocols are not one-size-fits-all. A risk-based strategy tailors the testing intensity, conditions, and duration based on factors like formulation type, lifecycle phase, market geography, and known degradation risks. This ensures that stability studies provide meaningful insights without overloading resources or delaying timelines. It…

Stability Study Tips

How ICH Stability Guidelines Differ for Biologics vs. Small Molecules

In pharmaceutical development, understanding how stability testing requirements differ between biologics and small molecule drugs is crucial for regulatory compliance. While both product types must meet ICH stability expectations, their testing parameters, degradation risks, and documentation differ significantly. This tutorial-style guide highlights the practical distinctions between ICH guidelines like Q1A and Q5C, with a focus…

ICH Stability Guidelines (Q1A–Q1E, Q8, Q9, etc.), Regulatory Guidelines

Step-by-Step Risk Assessment Process in QbD Stability Testing

In pharmaceutical development, integrating risk assessment into Quality by Design (QbD) transforms stability testing from a compliance exercise into a proactive quality tool. A structured approach using ICH Q9 principles and tools like FMEA (Failure Mode and Effects Analysis) ensures that critical risks are identified, scored, and controlled. This article provides a step-by-step instruction manual…

Pharmaceutical Quality and Practices, Quality by Design (QbD) in Stability Testing

Step-by-Step Guide to Updating Expiry Dates Post Stability Study

Pharmaceutical products undergo rigorous stability studies to determine their shelf life and assign appropriate expiry dates. However, as additional real-time stability data becomes available post-launch, it may justify extending a product’s shelf life and revising its expiry date. This guide provides a step-by-step walkthrough on how to update expiry dates following a stability study, in…

Shelf Life and Expiry, Shelf Life vs. Expiration Date: Key Differences